This study will evaluate the effects of dietary carbohydrate and sugar consumption, independent of energy content, on body fatness and metabolism in a rigorous feeding study.
Many people with obesity can lose weight for a few months, but most have difficulty maintaining weight loss over the long term. Extensive research has shown that weight loss elicits biological adaptations - including a decline in energy expenditure and an increase in hunger - that promote weight regain. However, this observation leaves unanswered why average body weight has recently increased among populations that are mostly genetically stable. According to the Carbohydrate-Insulin Model, increased consumption of processed carbohydrates during the low-fat diet era of the last 40 years has raised the average body weight being defended by biological mechanisms on a population basis. Specifically, the investigators hypothesize that diets high in total carbohydrate (with or without added sugar) acting through increased insulin secretion, alter substrate partitioning toward storage in body fat, leading to increased hunger, slowing metabolism, and accumulation of body fat. To test this hypothesis, the investigators plan a randomized-controlled feeding study involving 125 adults with obesity. During the run-in phase, participants will be given a hypocaloric very-low-carbohydrate (VLC) diet, with adjustment of energy intake to produce 15 ± 3% weight loss over 3 to 4 months on an outpatient basis. After weight stabilization, participants will be admitted to a residential center for 13 weeks. During the first 3 weeks, energy intake and expenditure will be closely monitored during weight-loss maintenance. Then, energy intake will be individually "locked" at levels equal to energy expenditure and participants will be administered one of three randomly-assigned test diets for 10 weeks. The test diets include VLC, High Carbohydrate-Low Sugar (HC-LS), and High Carbohydrate-High Sugar (HC-HS).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
166
Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
Warren Conference Center and Inn
Ashland, Massachusetts, United States
Body fat mass
Body composition assessed using a multi-component model
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Lean body mass
Assessed using a multi-component model (difference between total body mass and fat mass)
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Body weight
Anthropometrics, assessed by calibrated scale, in kilograms (kg)
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Total energy expenditure (TEE)
Assessed using doubly labeled water methodology
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Resting energy expenditure (REE)
Assessed by indirect calorimetry using respiratory gas exchange methodology with a ventilated hood system
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Physical activity level, (moderate to vigorous)
Total minutes of moderate- to vigorous-intensity physical activity, assessed by accelerometry
Time frame: Measurements made daily during 2 weeks at PWL, 2 weeks at END, and alternating non-assessment weeks of the residential phase and integrated into a unified outcome
Insulin sensitivity
Assessed by frequently-sampled oral glucose tolerance test \[OGTT\], calculated using plasma insulin and glucose values
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Insulin secretion
Assessed by frequently-sampled oral glucose tolerance test \[OGTT\], using plasma insulin at 30 minutes following the dose of dextrose
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Glycemic control
Hemoglobin A1c \[HbA1c\]
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Total cholesterol
Chronic disease risk factor
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
HDL-cholesterol
Chronic disease risk factor
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
LDL-cholesterol
Chronic disease risk factor
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Non-HDL cholesterol
Chronic disease risk factor
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Triglycerides
Chronic disease risk factor
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Plasminogen Activator Inhibitor-1 [PAI-1]
Indicator of coagulopathy
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
High-sensitivity C-reactive protein [hsCRP]
Indicator of chronic inflammation
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Uric acid
Indicator of risk for kidney stones, measured in blood
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Systolic blood pressure
Assessed by auscultation, mmHg
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Diastolic blood pressure
Assessed by auscultation, mmHg
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Thyroxine (T4)
Thyroid function
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Free T4
Thyroid function
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Thyroid stimulating hormone [TSH]
Thyroid function
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Insulin-like growth factor-1 [IGF-1]
Growth hormone action
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Urine cortisol
Stress hormone, assessed using 24-hour urine collection
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Urine catecholamines
Stress hormone, assessed using 24-hour urine collection
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Leptin
Adipokine
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Total Adiponectin
Adipokine
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
High-molecular weight adiponectin
Adipokine
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Sleep
Total sleep time, sleep onset latency, wake after sleep onset, and sleep efficiency, assessed by accelerometry
Time frame: Measurements made daily during 2 weeks at PWL, 2 weeks at END, and alternating non-assessment weeks of the residential phase and integrated into a unified outcome
Blood glucose
Assessed by continuous glucose monitoring (CGM)
Time frame: Measurements made daily during residential phase (0 to 10 weeks) and integrated into a unified outcome
Ghrelin
Hormonal Control of Appetite
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Body Circumference
Assessed using a 3D body scan
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)
Post-prandial energy expenditure and respiratory quotient
Optional testing, assessed by indirect calorimetry using respiratory gas exchange
Time frame: Single assessment in weeks 6 to 8 of residential study
Activation of insulin signaling pathways
Assessed by immunohistochemistry of phosphorylated insulin receptor and signaling proteins
Time frame: Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks)